Bank of America
VKTX icon

Bank of America’s Viking Therapeutics VKTX Stock Holding History

Bank of America’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,700
Closed -$109K – 7964
2023
Q2 		$109K Buy
+6,700
New +$140K ﹤0.01% 6163

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bank of America's VKTX Position: Q1 2026 in Review

Bank of America reduced its Viking Therapeutics (VKTX) stake by 4.6% in Q1 2026, selling an estimated $512K and leaving 330,720 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2893.

Bank of America first reported a position in VKTX in Q1 2018 and has held it in 33 quarters since. The position peaked at $33.8M in Q1 2024. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Bank of America held 330,720 shares of Viking Therapeutics worth $10.8M as of Q1 2026.
  • Bank of America sold 15,927 Viking Therapeutics shares in Q1 2026, an estimated $512K.
  • Viking Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2893 holding.
  • Bank of America first reported a position in Viking Therapeutics in Q1 2018 and has held it in 33 quarters since.
  • Bank of America's Viking Therapeutics position peaked at $33.8M in Q1 2024.
  • 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.